Xingui Liu

Xingui Liu, Ph.D.

Assistant Professor

Department: Medicinal Chemistry
Business Phone: (352) 294-5791
Business Email: xliu3@ufl.edu

About Xingui Liu

Xingui Liu joined the Department of Medicinal Chemistry at the College of Pharmacy, University of Florida as an Assistant Professor in 2023. Her research interest focuses on proximity agents-based early drug discovery, including hit identification, lead optimization, and assay development. Before starting her independent research career, Dr. Liu was a Marie Skłodowska-Curie fellow in Prof. Alessio Ciulli’s lab at the Center for Targeted Protein Degradation (CeTPD), University of Dundee where she developed PROTAC degraders of Leucine Rich Repeat Kinase 2 (LRRK2), a promising target for Parkinson’s disease. Prior to this, Xingui was a Postdoc associate at the University of Florida working with Prof. Guangrong Zheng and Prof. Daohong Zhou. She earned her PhD degree in Guangrong Zheng’s lab at the University of Arkansans for Medical Sciences, where she designed, synthesized, and characterized delta-tocotrienol based radio-protectors.

Teaching Profile

Courses Taught
2024
PHA6467C Drug Design II

Research Profile

Research in her laboratory is at the interface of chemistry and biology, focusing on discovering and developing small molecules that target E3 ligases, promote protein protein interactions, or induce protein degradation.

Areas of Interest
  • Medicinal chemistry
  • Small molecule drug discovery
  • Targeted protein degradation
Open Researcher and Contributor ID (ORCID)

0000-0003-2659-8007

Publications

2023
Piperlongumine conjugates induce targeted protein degradation.
Cell chemical biology. 30(2):203-213.e17 [DOI] 10.1016/j.chembiol.2023.01.004. [PMID] 36750097.
2023
Proximity-Based Modalities for Biology and Medicine.
ACS central science. 9(7):1269-1284 [DOI] 10.1021/acscentsci.3c00395. [PMID] 37521793.
2022
Discovery of XL01126: A Potent, Fast, Cooperative, Selective, Orally Bioavailable, and Blood-Brain Barrier Penetrant PROTAC Degrader of Leucine-Rich Repeat Kinase 2.
Journal of the American Chemical Society. 144(37):16930-16952 [DOI] 10.1021/jacs.2c05499. [PMID] 36007011.
2022
DUB be good to me.
Nature chemical biology. 18(4):358-359 [DOI] 10.1038/s41589-022-00978-9. [PMID] 35210617.
2021
Development of a BCL-xL and BCL-2 dual degrader with improved anti-leukemic activity.
Nature communications. 12(1) [DOI] 10.1038/s41467-021-27210-x. [PMID] 34824248.
2021
Discovery of a Novel BCL-XL PROTAC Degrader with Enhanced BCL-2 Inhibition.
Journal of medicinal chemistry. 64(19):14230-14246 [DOI] 10.1021/acs.jmedchem.1c00517. [PMID] 34533954.
2020
A Facile Semisynthesis and Evaluation of Garcinoic Acid and Its Analogs for the Inhibition of Human DNA Polymerase β.
Molecules (Basel, Switzerland). 25(24) [DOI] 10.3390/molecules25245847. [PMID] 33322249.
2020
Assays and technologies for developing proteolysis targeting chimera degraders.
Future medicinal chemistry. 12(12):1155-1179 [DOI] 10.4155/fmc-2020-0073. [PMID] 32431173.
2020
Deuteration of the farnesyl terminal methyl groups of δ-tocotrienol and its effects on the metabolic stability and ability of inducing G-CSF production.
Bioorganic & medicinal chemistry. 28(11) [DOI] 10.1016/j.bmc.2020.115498. [PMID] 32291146.
2020
PROTACs are effective in addressing the platelet toxicity associated with BCL-XL inhibitors.
Exploration of targeted anti-tumor therapy. 1(4):259-272 [DOI] 10.37349/etat.2020.00017. [PMID] 34296214.
2020
Synthesis and Liver Microsomal Metabolic Stability Studies of a Fluorine-Substituted δ-Tocotrienol Derivative.
ChemMedChem. 15(6):506-516 [DOI] 10.1002/cmdc.201900676. [PMID] 31957223.
2020
Targeting anti-apoptotic BCL-2 family proteins for cancer treatment.
Future medicinal chemistry. 12(7):563-565 [DOI] 10.4155/fmc-2020-0004. [PMID] 32083493.
2020
Using proteolysis-targeting chimera technology to reduce navitoclax platelet toxicity and improve its senolytic activity.
Nature communications. 11(1) [DOI] 10.1038/s41467-020-15838-0. [PMID] 32332723.
2019
A selective BCL-XL PROTAC degrader achieves safe and potent antitumor activity.
Nature medicine. 25(12):1938-1947 [DOI] 10.1038/s41591-019-0668-z. [PMID] 31792461.
2019
Utilizing PROTAC technology to address the on-target platelet toxicity associated with inhibition of BCL-XL.
Chemical communications (Cambridge, England). 55(98):14765-14768 [DOI] 10.1039/c9cc07217a. [PMID] 31754664.
2018
Oxidation resistance 1 is a novel senolytic target.
Aging cell. 17(4) [DOI] 10.1111/acel.12780. [PMID] 29766639.
2018
Senolytic activity of piperlongumine analogues: Synthesis and biological evaluation.
Bioorganic & medicinal chemistry. 26(14):3925-3938 [DOI] 10.1016/j.bmc.2018.06.013. [PMID] 29925484.
2016
Discovery of piperlongumine as a potential novel lead for the development of senolytic agents.
Aging. 8(11):2915-2926 [DOI] 10.18632/aging.101100. [PMID] 27913811.
2016
Synthesis of (2R,8′ S,3′ E)-δ-tocodienol, a tocoflexol family member designed to have a superior pharmacokinetic profile compared to δ-tocotrienol.
Tetrahedron. 72(27-28):4001-4006 [PMID] 27773949.
2014
A mild and efficient AgSbF6-catalyzed synthesis of fully substituted pyrroles through a sequential propargylation/amination/cycloisomerization reaction.
Tetrahedron. 70(34):5267-5273 [PMID] 25061238.

Contact Details

Phones:
Business:
(352) 294-5791
Emails:
Business:
xliu3@ufl.edu
Addresses:
Business Mailing:
PO Box 100485
GAINESVILLE FL 32610
Business Street:
1345 CENTER DR
GAINESVILLE FL 32610